Decoding Neurological Disease. Building Precision Medicines.

CELLTIUM is developing precision therapeutics for CMT1A and related inherited peripheral neuropathies. By integrating deep disease biology with its proprietary PRECISION™ platform, CELLTIUM translates biological insight into targeted, disease-modifying drug candidates.

CELLTIUM is building a new neurotherapeutics model through a unified discovery engine that combines disease-relevant models, quantitative phenotyping, multimodal data, and AI/ML to accelerate target discovery and lead development.

The precision pipeline is designed to address the core biology of CMT1A and related inherited peripheral neuropathies. The goal is to move beyond symptom management toward therapies that preserve or restore peripheral nerve function.

CELLTIUM welcomes strategic partnerships with biopharma companies, investors, and patient advocacy organizations to advance the lead CMT1A program into the clinic and expand the reach of the PRECISION™ platform across rare neurology.